NCT03870841 is a Phase 2 clinical trial of PC945 in Aspergillosis, sponsored by Pulmocide Ltd.

Who is sponsoring NCT03870841?

NCT03870841 is sponsored by Pulmocide Ltd.

What drugs are being tested in NCT03870841?

Interventions in NCT03870841: PC945.

What condition does NCT03870841 study?

NCT03870841 studies Aspergillosis, Cystic Fibrosis.

Is NCT03870841 still recruiting?

NCT03870841 is currently terminated. Last updated 16 July 2021.

Last reviewed 2021-07-16 · How we verify

NCT03870841

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis

Terminated Phase 2 Last updated 16 July 2021

What this trial tests

Phase 2 trial testing PC945 in Aspergillosis in 4 participants. Terminated before completion.

Timeline

3 April 2019

Primary endpoint
1 June 2020

1 June 2020

Quick facts

Lead sponsor	Pulmocide Ltd
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	3 April 2019
Primary completion	1 June 2020
Estimated completion	1 June 2020
Sites	2 locations across United Kingdom

Drugs / interventions tested

PC945 — full drug profile →

Conditions studied

Aspergillosis — all drugs for Aspergillosis →
Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Pulmocide Ltd — full company profile →

Who can join

18 and older, any sex, with Aspergillosis or Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study tests the effects of an experimental drug PC945 in people with cystic fibrosis whose lungs are infected by the fungus Aspergillus fumigatus. PC945 may be useful in treating patients infected with Aspergillus fumigatus as, unlike the usual treatments, it is inhaled into the lung and has been designed to stay there and treat the infection. Participants will continue to be treated with their usual cystic fibrosis treatment and will also receive PC945. The amount of fungus in the patients' phlegm will be measured over the course of the study. The study will take place at multiple sites in UK and will include approximately 18 participants. The maximum study duration will be about 16 weeks.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

New Antifungal Agents with Azole Moieties.
Teixeira MM, Carvalho DT, Sousa E, Pinto E. · · 2022 · cited 44× · PMID 36422557 · DOI 10.3390/ph15111427
Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug <i>Candida auris</i>.
Billamboz M, Fatima Z, Hameed S, Jawhara S. · · 2021 · cited 39× · PMID 33803604 · DOI 10.3390/microorganisms9030634

Verify or expand the search:

Other trials of PC945

Trials testing the same drug.

NCT05238116 — Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory · Phase 3 · terminated
NCT03905447 — The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. · Phase 2 · terminated
NCT03745196 — The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases · Phase 2 · terminated

Other recruiting trials for Aspergillosis

Currently open trials in the same condition.

NCT05045391 — Pulmonary Aspergillosis in Tuberculosis Patients · active not recruiting
NCT03828773 — PTX3-targeted Antifungal Prophylaxis · NA · recruiting

Other Pulmocide Ltd trials

Trials by the same sponsor.

NCT05238116 — Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory · Phase 3 · terminated
NCT05037851 — A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transp · Phase 2 · completed
NCT03905447 — The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. · Phase 2 · terminated
NCT03745196 — The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases · Phase 2 · terminated
NCT03715023 — Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03870841 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pulmocide Ltd
Last refreshed: 16 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03870841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing